Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

Table 2 Proportion of patients with NDM requiring resources in the UK

Health resource^a	Round 1 (n = 5, 1 drop-out)				Round 2 (n = 4, 1 drop-out)
Health resource^a	BSC – Mean % of patients requiring resource (range)	Mexiletine – Mean % of patients requiring resource (range)	Difference (%)	BSC:mexiletine ratio^b	% Agreement that HRU is on average lower for patients treated with mexiletine among panel (% agreement among responders)
Physiotherapy	39.0 (15–60)	23.0 (5–60)	−16.0	1.7	60% (75%)
Occupational therapist	15.0 (5–25)	6.0 (0–15)	−9.0	2.5	60% (75%)
Speech therapy	5.0 (0–15)	1.0 (0–5)	−4.0	5.0	40% (50%)
Day case attendances	60.0 (0–100)	60.0 (0–100)	0.0	0	NA
Wheelchair	4.2 (0–20)	4.2 (0–20)	0.0	0	NA
Walking stick	7.2 (0–30)	2.2 (0–10)	−5.0	3.3	60% (75%)
Walking frame	0.4 (0–2)	0.0 (0–0)	−0.4	0	60% (75%)
Hospital admission for fracture	3.0 (0–10)	1.0 (0–5)	−2.0	3.0	60% (75%)
Overall BSC:mexiletine (NaMuscla) ratio				1.9	60% (75%)
Mental health support	38 (20–60)	14 (5–20)	−24	2.7	83% (100%)

Key: BSC Best supportive care (defined as any supportive care that symptomatic adult patients with NDM may receive that does not involve symptom-modifying pharmacological treatment; includes, for example, the use of supportive medication [e.g. pain killers], mobility aids, physiotherapy or speech therapy), HRU Healthcare resource utilization, NDM Non-dystrophic myotonia
^aThe rows in bold indicate resources for which there was consensus
^bThe ratio was calculated by dividing the mean proportion of patients receiving BSC that require a resource by the mean proportion of patients treated with mexiletine (NaMuscla) that require the resource

ISSN: 1471-2377